What are personalised cancer treatments?
A personalised cancer treatment takes into account the different characteristics of each person’s melanoma and uses this to make a very specific treatment to target, attack and kill their own melanoma cells.
What is an Investigational Neoantigen Treatment (INT)?
An INT is a type of personalised cancer treatment.
Scientists take cells from a person’s melanoma and look at them in a laboratory to identify the neoantigens, which are proteins on the tumour cells that the body’s immune system can recognise. The scientists can then create a treatment that when given back to the same patient can stimulate their body’s immune system to recognise these neoantigens on the melanoma cells’ surface so that it can attack and kill them.
There are different types of new technologies used to make INT’s and this trial will be using an mRNA -based INT. With mRNA being the messenger system which can instruct the body to make certain proteins.
This phase 3 clinical trial by MSD and Moderna will be the first of its kind looking at an mRNA-based INT to treat melanoma patients in the UK.
For more information on this news please see the announcement here
For more information on current clinical trials available to melanoma patients see our Melanoma TrialFinder.
And remember to keep checking back for news on this new trial which is hopefully planned to open in late 2023!